Amedisys (AMED) Management Meeting Offers 4 Key Takeaways - BofA Securities

BofA Securities analyst Joanna Gajuk reiterated a Neutral rating and $180.00 price target on Amedisys (NASDAQ: AMED) after meeting with Scott Gin, CFO, Chris Gerard, COO, and Nick Muscato, SVP of Finance. The meetings offered 4 key takeaways:
1) continues to expect 5-7% organic growth LT given the strong demand, noting 2022 is a challenging year
2) labor environment improving
3) as % of staff on quarantine declined, home health admits accelerated through the quarter
4) traction on MA rates

The analyst stated "while the tone was positive, we maintain our Neutral rating as the hospice business might take time to recover, and we remain bullish on the long-term outlook."

For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.

Shares of Amedisys closed at $172.29 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)